Onset Time of Brachial Plexus Block Using Local Anaesthetic Diluted With 0.9% Saline vs 5% Dextrose

Sponsor
University of Malaya (Other)
Overall Status
Completed
CT.gov ID
NCT01815944
Collaborator
(none)
55
1
2
10
5.5

Study Details

Study Description

Brief Summary

Regional anesthesia employs the use of local anesthetics (LA) to block specific nerves to enable pain free surgery to be performed, or for intra and post operative pain relief. Dilution of local anesthetics with normal saline (NS) is a common practice to enable larger volumes of LA to be given, for example, in instances where multiple nerve blocks are needed to be performed for optimal pain relief while avoiding toxic doses.

A high sodium concentration is known to antagonize the analgesic effect of local anesthetics. 5% dextrose (D5W) on the other hand is painless on injection and does not cause any long-term effects in animals or humans when injected around neurological tissue. In the literature, only one study using dextrose 5% as diluent to produce 0.5% ropivacaine for axillary brachial plexus block showed a statistically significant reduction in the onset time for sensory blockade when compared with dilution with NS.

In this study, 0.5% ropivacaine diluted with D5W or NS is used for ultrasound guided supraclavicular brachial plexus block, and the time for complete sensory and motor blockade was compared. 0.5% ropivacaine is easily diluted and is a common concentration used at our centre for nerve blocks. The aim of this study is to assess if 0.5% ropivacaine diluted with D5W results in a shorter onset time for sensory block which may change the current practice of dilution with NS

Condition or Disease Intervention/Treatment Phase
  • Drug: 0.75% Ropivacaine
  • Drug: Normal saline
  • Drug: Dextrose 5%
N/A

Detailed Description

  • Patients randomly assigned to receive either 0.5% ropivacaine diluted with NS or D5W.

  • Randomization followed a computer-generated randomization table and patients are blinded as to their group allocation.

  • Group allocations are concealed in a sealed opaque envelope and only known to an independent anaesthesia trainee who prepares 20mls 0.5% ropivacaine

  • The anaesthesiologist involved in the performance of the supraclavicular brachial plexus block is blinded to group allocation

  • All ultrasound-guided supraclavicular blocks are performed by 2 anaesthesiologists who are familiar with the technique.

  • A trained anaesthesiology trainee who is blinded to group allocation evaluated sensory loss and motor blockade every 5 mins after injection of local anaesthetic.

  • The extent of sensory loss is tested in the median, radial, ulnar, and musculocutaneous nerve distributions and evaluated using a 3-point score: 2 = normal sensation, 1 =loss of sensation to pinprick (ie, analgesia), or 0 = loss of sensation to light touch (ie, anesthesia). The extent of motor blockade is tested in the distribution of the radial (thumb abduction), ulnar (thumb adduction), musculocutaneous (flexion of the elbow in supination and pronation), and median nerves (thumb opposition) and evaluated using a 3-point scale where 2 = normal movement, 1 = paresis, and 0 = absent movement.

  • Block success is defined as loss of sensation to pinprick (sensory score 1) in each of the radial, ulnar, median, and musculocutaneous nerve distributions measured 60 mins after the end of local anaesthetic injection. Patients in whom block success was not achieved after 60 mins were excluded from data analysis.

  • During the postoperative recovery period, pain (verbal response score 4 or patient request for analgesic) is treated with IV tramadol 25-50 mg slow bolus with or without fentanyl 25mcg boluses every 5 minutes as needed.

  • When oral intake is allowed, patients will receive oral paracetamol 1g with oral diclofenac 50 mg or celecoxib 200mg, if not contraindicated.

  • The block duration is subsequently taken as time from complete analgesia to the time when the patient first feels the slightest pain from the operative site.

  • Patients are followed up twice; once on post-operative day (POD) 1 and once between POD 7-10.

  • They are seen in the ward or are contacted via telephone and asked for the presence of any pain, weakness, numbness, tingling, or any abnormal sensation in the operative extremity.

  • If indicated, they are then told to come to hospital for further evaluation and management as necessary.

Study Design

Study Type:
Interventional
Actual Enrollment :
55 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Onset Time of Brachial Plexus Block Using Local Anaesthetic Diluted With 0.9% Saline vs 5% Dextrose
Study Start Date :
Dec 1, 2011
Actual Primary Completion Date :
Oct 1, 2012
Actual Study Completion Date :
Oct 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 0.75% Ropivacaine and normal saline

Ultrasound-guided supraclavicular block using 0.75% ropivacaine diluted with normal saline

Drug: 0.75% Ropivacaine
Other Names:
  • Naropin
  • Drug: Normal saline

    Experimental: 0.75% ropivacaine and dextrose 5%

    Ultrasound guided supraclavicular block using 0.75% ropivacaine diluted with dextrose 5%

    Drug: 0.75% Ropivacaine
    Other Names:
  • Naropin
  • Drug: Dextrose 5%

    Outcome Measures

    Primary Outcome Measures

    1. Onset time for sensory blockade [60 minutes]

    Secondary Outcome Measures

    1. Duration of sensory blockade [12 hours]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • ASA I to III

    • elective or emergency surgery of the hand, forearm and elbow

    Exclusion Criteria:
    • diabetes mellitus

    • neurological deficit

    • contraindications to supraclavicular brachial plexus blockade

    • unable to give consent

    • patient refusal

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Malaya Medical Centre Kuala Lumpur Malaysia 59100

    Sponsors and Collaborators

    • University of Malaya

    Investigators

    • Principal Investigator: M. Shahnaz Hasan, MBBS, M Anes, University of Malaya

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr Mohd Shahnaz, Dr, University of Malaya
    ClinicalTrials.gov Identifier:
    NCT01815944
    Other Study ID Numbers:
    • UMMC883.11
    First Posted:
    Mar 21, 2013
    Last Update Posted:
    Mar 21, 2013
    Last Verified:
    Mar 1, 2013
    Keywords provided by Dr Mohd Shahnaz, Dr, University of Malaya
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 21, 2013